Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multi-Center Study of ManNAc for GNE Myopathy (MAGiNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04231266
Recruitment Status : Not yet recruiting
First Posted : January 18, 2020
Last Update Posted : February 6, 2020
Sponsor:
Collaborators:
Brigham and Women's Hospital
National Human Genome Research Institute (NHGRI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Neurological Disorders and Stroke (NINDS)
Leadiant Biosciences, Inc.
Information provided by (Responsible Party):
William A. Gahl, MD, PhD, National Human Genome Research Institute (NHGRI)

Tracking Information
First Submitted Date  ICMJE January 8, 2020
First Posted Date  ICMJE January 18, 2020
Last Update Posted Date February 6, 2020
Estimated Study Start Date  ICMJE February 1, 2020
Estimated Primary Completion Date January 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 13, 2020)
Muscle strength of ankle dorsiflexion, knee flexion, knee extension, shoulder abduction, elbow flexion and grip measured by fixed-frame Quantitative Muscle Assessment (QMA) [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
The primary endpoint is the change in muscle strength decline under treatment compared to placebo. Muscle strength is measured by the Quantitative Muscle Assessment (QMA; Aeverl Medical). The primary analysis is based on the disease progression ratio (γ) comparing the rate of progression from baseline until last visit, under placebo to that under treatment.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 13, 2020)
GNE Myopathy Physical Function Scale (GNEM-PFS) [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
The effect of ManNAc on patient reported physical functioning will be assessed by the GNE Myopathy Physical Function Scale (GNEM-PFS). This is a newly developed, disease-specific patient-reported outcome that consists of 18 items scored on an 11-point numerical rating scale (NRS) from 0 (no difficulty) to 10 (unable to do) where lower scores indicate better patient reported physical functioning. The GNEM-PFS is assessed at baseline and then again every six months until 24 months after the final subject is randomized. Change from baseline to each follow-up time point on the 18-item Total score will be calculated, and comparisons between the ManNAc group and placebo group will be based on a linear mixed effects model.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: January 13, 2020)
  • Adverse Events [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Safety of orally administered ManNAc will be compared to placebo.
  • Correlation muscle strength measured by QMA and the GNEM-PFS. [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate the correlation between QMA assessments and patient-reported physical functioning assessed by GNEM-PFS.
  • Adult Myopathy Assessment Tool [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate the effect of ManNAc on physical function as measured by the Adult Myopathy Assessment Tool (AMAT), a 13-item standardized test that assesses physical performance, to be performed at baseline and every 6 months thereafter until completion of the study.
  • Six-Minute Walk Test [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate the effect of ManNAc on physical function as measured by the Six-Minute Walk Test (whenever possible) to be performed at baseline and every 6 months thereafter until completion of the study.
  • Timed Up and Go Test [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate the effect of ManNAc on physical function as measured by the Timed Up and Go, performance test to evaluate functional mobility, to be performed at baseline and every 6 months thereafter until completion of the study.
  • Functional Reach Test [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate the effect of ManNAc on physical function as measured by the Functional Reach, a measure of stability, to be performed at baseline and every 6 months thereafter until completion of the study.
  • Jebsen Hand Function Test [ Time Frame: Baseline and every 12 months thereafter ]
    Evaluate the effect of ManNAc on physical function as measured by the Jebsen Hand Function Test, a performance measure which assesses unilateral hand function, to be performed at baseline and every 6 months thereafter until completion of the study.
  • Inclusion Body Myositis Functional Rating Scale [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate effect of ManNAc on activities of daily living (ADLs) compared to placebo as measured by the Inclusion Body Myositis Functional Rating Scale (IBMFRS), a patient-reported outcome completed at baseline, and every 6 months thereafter until completion of the study.
  • Human Activity Profile [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate effect of ManNAc on activities of daily living (ADLs) compared to placebo as measured by the Human Activity Profile, a patient-reported outcome completed at baseline, and every 6 months thereafter until completion of the study.
  • Activities-specific Balance Confidence (ABC) scale [ Time Frame: Minimum 2 years, until 24 months from randomization of last subject ]
    Evaluate effect of ManNAc on activities of daily living (ADLs) compared to placebo as measured by the Activities-specific Balance Confidence (ABC) scale, a patient-reported outcome completed at baseline, and every 6 months thereafter until completion of the study.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Multi-Center Study of ManNAc for GNE Myopathy
Official Title  ICMJE A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy
Brief Summary GNE myopathy is a rare genetic muscle disease characterized by progressive muscle atrophy and weakness. The disease is caused by mutations in the gene that encodes the enzyme that initiates and regulates N-acetylneuraminic acid (Neu5Ac) biosynthesis and glycan sialylation. Currently, there is no therapy available for this disease. N-Acetylmannosamine (ManNAc), an orphan drug in development for GNE myopathy, is an uncharged monosaccharide and the first committed precursor in Neu5Ac biosynthesis. In this randomized, double-blind, placebo-controlled trial the efficacy and long-term safety of ManNAc will be evaluated in subjects with GNE myopathy.
Detailed Description

This is a randomized, placebo-controlled, double-blind, multi-center study to evaluate the long-term safety and clinical efficacy of ManNAc in subjects with GNE myopathy.

A total of 51 eligible subjects will be randomized in a 2:1 ratio to receive either ManNAc at 4 g three times daily (total of 12 g/day) or placebo. Subjects will have follow-up visits every 6 months (±7 days) and take study drug for a minimum of 24 months, until their final study visit . The final on-site study visit for a subject is the last expected 6-month follow-up visit that occurs prior to the time the last randomized subject is expected to reach 24 months (extended follow-up).

Subjects will undergo screening and baseline evaluations that include clinical laboratory tests, Quantitative Muscle Assessment (QMA), the GNE Myopathy Physical Function Scale (GNEM-PFS), other patient-reported outcomes (PROs), and rehabilitation medicine functional assessments. Follow-up evaluations will occur every six months following baseline, until 24 months after randomization of the last subject. Phone follow-up will occur every month without a clinic visit for the duration of the trial, and the last visit for each subject will be followed by phone follow-up 1 month after stopping study drug.

The primary endpoint is the change in muscle strength of ankle dorsiflexion, knee flexion, knee extension, shoulder abduction, elbow flexion and grip reported as proportion of predicted strength. Muscle strength will be measured by fixed-frame Quantitative Muscle Assessment (QMA; Aeverl Medical).

The primary analysis is based on comparing the rate of disease progression under placebo to that under treatment. The design of the trial is based on a Disease Progression Model of GNE myopathy that was generated using QMA muscle strength data collected in subjects with GNE myopathy as part of a prospective Natural History Study of the disease.

It was estimated that 51 subjects with 2:1 randomization (ManNAc: Placebo) will provide a power of 89% under a treatment-related slowing in the rate of decline of 50% and a Type I error of 1%, accounting for lost-to follow-up and intend to treat analysis.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE GNE Myopathy
Intervention  ICMJE
  • Drug: ManNAc
    Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
    Other Name: N-acetyl-D-mannosamine monohydrate
  • Other: Placebo
    Placebo
Study Arms  ICMJE
  • Active Comparator: ManNAc
    Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
    Intervention: Drug: ManNAc
  • Placebo Comparator: Placebo
    Oral Placebo will be administered three times daily.
    Intervention: Other: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: January 13, 2020)
51
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 31, 2023
Estimated Primary Completion Date January 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject should be 18-70 years of age at the time of enrollment, inclusive, and of either gender.
  2. Subject has a diagnosis of GNE myopathy based upon a consistent clinical course and biallelic GNE gene mutations.
  3. Subjects must have 10-65% of predicted muscle strength measured by QMA at screening in at least one of the selected muscle groups (ankle dorsiflexion, knee flexion, grip, shoulder abduction and elbow flexion).
  4. Subject has the ability to travel to the Clinical Trial Site for visits.
  5. Subjects must be able to communicate effectively with study staff and understand the requirements of the protocol without translators.
  6. Subject must be able to comply with requirements of the protocol, including blood collection, drug administration, and muscle strength assessments.
  7. Women of childbearing potential must be willing to use an effective method of contraception for the duration of the trial. It is recommended that male subjects follow birth control measures for the duration of the trial.
  8. Subject must be able to provide informed consent.

Exclusion Criteria:

  1. Subject had an infection or medical illness requiring intravenous antibiotics or hospitalization within 30 days prior to the baseline/randomization visit.
  2. Subject has another comorbid condition which may affect physical function.
  3. Subject has a psychiatric illness or neurological disease that would interfere with the ability to comply with the requirements of this protocol.
  4. Subject with hepatic laboratory parameters (AST, ALT, GGTP), equal to or greater than 3 times the upper limit of normal at screening.
  5. Subject with existing renal dysfunction, as defined by glomerular filtration rate (GFR) less than 60 ml/min/m2 at screening.
  6. Subject is anemic (defined as hematocrit <30%) or has platelets <75,000 or white blood cell count less than 3,000/mL at screening.
  7. Subject shows evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires immediate surgical intervention.
  8. Subject is pregnant or breastfeeding at any time during the study.
  9. Subject has received treatment with another investigational drug, investigational device, or approved therapy for investigational use less than 90 days prior to screening.
  10. Subject has received any dose of ManNAc, sialic acid, intravenous immunoglobulin (IVIG), and/or other compounds containing, or that can be metabolized into sialic acid, within 6 months prior to enrollment as reported by subject at the time of screening.
  11. Subject has received ManNAc, sialic acid, IVIG and/or other compounds containing, or that can be metabolized into sialic acid, for a cumulative total of more than 30 days within 1 year of enrolling in this trial.
  12. Subject has received stem cell therapy or gene therapy within 1 year prior to screening.
  13. Subject has hypersensitivity to ManNAc or erythritol or in the judgment of the investigator, has a condition that places the subject at increased risk for adverse effects.
  14. The presence of persistent diarrhea or malabsorption that could interfere with the subject's ability to absorb drugs or to tolerate ManNAc therapy.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: David Klements, MS, CCRP 617-726-3430 DKlements@mgh.harvard.edu
Contact: Timothy Leonard, BS 617-726-5782 TPLeonard@partners.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04231266
Other Study ID Numbers  ICMJE NN109
1U01AR070498-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party William A. Gahl, MD, PhD, National Human Genome Research Institute (NHGRI)
Study Sponsor  ICMJE William A. Gahl, MD, PhD
Collaborators  ICMJE
  • Brigham and Women's Hospital
  • National Human Genome Research Institute (NHGRI)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • Leadiant Biosciences, Inc.
Investigators  ICMJE
Principal Investigator: Anthony A. Amato, MD Brigham and Women's Hospital
Principal Investigator: Nuria Carrillo, MD National Human Genome Research Institute (NHGRI), NIH
PRS Account National Human Genome Research Institute (NHGRI)
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP